Insider · CIK 0001704021
John E. Friend II
Files at KZIA (KAZIA THERAPEUTICS LTD). First filing -, latest -.
In brief
John E. Friend II files SEC Form 4 as CEO at KZIA (KAZIA THERAPEUTICS LTD). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John E. Friend II has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | KZIA KAZIA THERAPEUTICS LTD | AGrant or award Employee Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jul 8, 2026 |
| Jan 8, 2026 | KZIA KAZIA THERAPEUTICS LTD | AGrant or award Restricted Share Unitsderivative | -150,000 | $0.00 | $0 | 150,000 | Jul 8, 2026 |
Questions about John E. Friend II
Answered from the filings on this page, as of the latest one.
Is John E. Friend II buying or selling?
John E. Friend II has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John E. Friend II's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John E. Friend II has 0.
Where does John E. Friend II file Form 4?
John E. Friend II has filed Form 4 at KZIA (KAZIA THERAPEUTICS LTD) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.